Breast Cancer Surgery Articles & Analysis
39 news found
Dirbas in 2002 was an early adopter of accelerated, partial breast irradiation for surgical patients with early-stage breast cancer and served as Primary Investigator (PI) on Stanford’s successful investigator initiated APBI trial: he has also served as site-PI for other cooperative group trials related to breast ...
Targeting peak sales potential of $1 billion in the major markets Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, is pleased to announce that it has now finalised plans for its Phase 3 studies for its late-stage clinical asset, XF-73 Nasal. Highlights Discussions held ...
This clinical investigation called TIDE, had a first successful implantation by 12th of July at the Institute of Clinical Oncology with a 63 years old patient operated with MATTISSE in the case of her breast cancer and immediate reconstruction. CE marking, industrialisation and hiring for the marketing of MATTISSE The second objective of this fundraising is to ...
After the entry into clinical phase announced in early July 2022, LATTICE MEDICAL, announces the success of the first breast reconstruction operation with the MATTISSE implant. The operation took place on July 12 at the Institute of Clinical Oncology, Tbilisi, Georgia. It was conducted by Pr Gia Nemsdaze and his team, and in the presence of the co-founders of Lattice Medical, Pr. Pierre ...
(TSX-V:PINK)(OTC:PYNKF) (FSE:4PC) (“Perimeter” or the “Company”) – a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs – today jointly announced the first commercial placement of the Perimeter S-Series OCT system in the ...
QView Medical is pleased to announce FDA approval for QVCAD to be used with the GE Invenia™ ABUS in breast screening for asymptomatic dense breasted women whose mammogram was negative. QVCAD is the next generation CAD system for automated breast ultrasound ("ABUS") based on deep learning algorithms. The QVCAD innovative C-Thru technology combined with ABUS has demonstrated a 33% improved ...
National Institutes of Health (NIH)’s National Cancer Institute (NCI) to advance development of its proprietary device for Fluorescence-Guided Surgery (FGS). ...
Patients with DCIS have cancerous cells lining the milk ducts of the breast, but they have not spread into surrounding breast tissue. ...
Patients with DCIS have cancerous cells lining the milk ducts of the breast, but they have not spread into surrounding breast tissue. ...
Patients with DCIS have cancerous cells lining the milk ducts of the breast, but they have not spread into surrounding breast tissue. ...
CMR Surgical & Surgical Innovations develop new surgical hybrid port access system Surgical Innovations’ new YelloPort Elite™ 5mm, with reusable trocar and canula, reduces cost and waste generated when compared with traditional fully single use Port Access Systems Developed with CMR Surgical, the port access system is the latest addition to Surgical Innovation’s ...
Patients with DCIS have cancerous cells lining the milk ducts of the breast, but they have not spread into surrounding breast tissue. ...
Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced it will be presenting data comparing DCISionRT? ...
Approximately 300 patients undergoing breast conservation surgery across eight U.S. clinical sites are expected to participate in the pivotal trial, with study completion anticipated by the end of 2022. ...
(TSX-V:PINK)(OTC:PYNKF) (FSE:4PC) (“Perimeter” or the “Company”), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, announced the initiation of a multi-center, randomized, two-arm pivotal clinical trial to evaluate its Perimeter ...
Updated RxPONDER study analysis provides further evidence that the test identifies the majority of women with early-stage, node-positive breast cancer who can avoid chemotherapy Exact Sciences Corp. (NASDAQ: EXAS), a global leader in cancer diagnostics, today announced the presentation of new data at the 2021 San Antonio ...
Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced the publication of SweDCIS randomized clinical trial data in the Special Issue: Updates on Breast Cancer edition of Cancers. ...
Alastair Thompson, Principal Investigator and Professor, Section Chief of Breast Surgery and Olga Keith Wiess Chair of Surgery at Baylor College of Medicine and the Dan L Duncan Comprehensive Cancer Center said, “Currently, approximately one in four women who undergo breast conservation ...
Hisanori Kawamoto, MD, PhD. from the Department of Breast Surgery Breast and Imaging Center, St. Marianna University School of Medicine, Japan. “We are excited to see the publication of this data from an independent study which further supports the use of our ProSense™ Cryoablation System to eliminate small malignant lesions in the ...
Study Demonstrate Superiority of VeraForm® Marker Over Clips For Tumor Bed Delineation Accuracy San Francisco CA, October 28, 2021- Videra Surgical Inc., the developer of the novel adaptable tumor bed marker VeraForm® for breast cancer surgery, announced the presentation of an independent study at this week’s ASTRO ...